Gemcitabine Maintenance in Lung Cancer Could Be Low Cost Alternative
This video highlights a study that tested an alternative maintenance strategy determined by response to induction chemotherapy for patients with advanced non-squamous non–small-cell lung cancer.
In this video, Maurice Pérol, MD, of the Cancer Research Center of Lyon in France, discusses a study that tested an alternative maintenance strategy for advanced non-squamous non–small-cell lung cancer (NSCLC), determined by a patient’s response to induction chemotherapy.
Patients in the study were randomized 1:1 to either cisplatin/gemcitabine induction followed by gemcitabine maintenance in those with an objective response and then second-line pemetrexed, or switch maintenance with pemetrexed for those with stable disease; vs standard cisplatin/pemetrexed induction followed by maintenance pemetrexed.
Pérol presented the results of the study (abstract 9003) at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago..
Neoadjuvant Capecitabine Plus Temozolomide in Atypical Lung NETs
Read about a woman with well-differentiated atypical carcinoid who experienced a 21% regression in primary tumor size after 12 months on neoadjuvant capecitabine and temozolomide.
